These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 18974135)

  • 1. ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer.
    Riggins RB; Lan JP; Zhu Y; Klimach U; Zwart A; Cavalli LR; Haddad BR; Chen L; Gong T; Xuan J; Ethier SP; Clarke R
    Cancer Res; 2008 Nov; 68(21):8908-17. PubMed ID: 18974135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.
    Stires H; Heckler MM; Fu X; Li Z; Grasso CS; Quist MJ; Lewis JA; Klimach U; Zwart A; Mahajan A; Győrffy B; Cavalli LR; Riggins RB
    Mol Cell Endocrinol; 2018 Aug; 471():105-117. PubMed ID: 28935545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.
    Madhavan S; Gusev Y; Singh S; Riggins RB
    J Exp Clin Cancer Res; 2015 May; 34(1):45. PubMed ID: 25971350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
    Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
    Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer.
    Heckler MM; Thakor H; Schafer CC; Riggins RB
    FEBS J; 2014 May; 281(10):2431-42. PubMed ID: 24684682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.
    Sikora MJ; Cooper KL; Bahreini A; Luthra S; Wang G; Chandran UR; Davidson NE; Dabbs DJ; Welm AL; Oesterreich S
    Cancer Res; 2014 Mar; 74(5):1463-74. PubMed ID: 24425047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma.
    Bossart EA; Tasdemir N; Sikora MJ; Bahreini A; Levine KM; Chen J; Basudan A; Jacobsen BM; Burns TF; Oesterreich S
    Breast Cancer Res Treat; 2019 Jun; 175(2):327-337. PubMed ID: 30798422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of AKR1 family in tamoxifen resistant invasive lobular breast cancer based on data mining.
    Xu D; Zhang Y; Jin F
    BMC Cancer; 2021 Dec; 21(1):1321. PubMed ID: 34886806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast.
    Sottnik JL; Bordeaux EK; Mehrotra S; Ferrara SE; Goodspeed AE; Costello JC; Sikora MJ
    Mol Cancer Res; 2021 Aug; 19(8):1270-1282. PubMed ID: 33947745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
    Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
    Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer.
    Du T; Sikora MJ; Levine KM; Tasdemir N; Riggins RB; Wendell SG; Van Houten B; Oesterreich S
    Breast Cancer Res; 2018 Sep; 20(1):106. PubMed ID: 30180878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
    Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
    Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].
    Zhen LL; Zhu X; Zheng W; Wang XY; Wu ZY
    Ai Zheng; 2006 Jul; 25(7):839-43. PubMed ID: 16831274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.
    Shah N; Jin K; Cruz LA; Park S; Sadik H; Cho S; Goswami CP; Nakshatri H; Gupta R; Chang HY; Zhang Z; Cimino-Mathews A; Cope L; Umbricht C; Sukumar S
    Cancer Res; 2013 Sep; 73(17):5449-58. PubMed ID: 23832664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
    Nardone A; Qiu X; Spisak S; Nagy Z; Feiglin A; Feit A; Cohen Feit G; Xie Y; Font-Tello A; Guarducci C; Hermida-Prado F; Syamala S; Lim K; Munoz Gomez M; Pun M; Cornwell M; Liu W; Ors A; Mohammed H; Cejas P; Brock JB; Freedman ML; Winer EP; Fu X; Schiff R; Long HW; Metzger Filho O; Jeselsohn R
    Cancer Res; 2022 Oct; 82(20):3673-3686. PubMed ID: 35950920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoplasmic PELP1 and ERRgamma protect human mammary epithelial cells from Tam-induced cell death.
    Girard BJ; Regan Anderson TM; Welch SL; Nicely J; Seewaldt VL; Ostrander JH
    PLoS One; 2015; 10(3):e0121206. PubMed ID: 25789479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.
    van de Water W; Fontein DB; van Nes JG; Bartlett JM; Hille ET; Putter H; Robson T; Liefers GJ; Roumen RM; Seynaeve C; Dirix LY; Paridaens R; Kranenbarg EM; Nortier JW; van de Velde CJ
    Eur J Cancer; 2013 Jan; 49(2):297-304. PubMed ID: 22954666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
    Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
    Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.